BS-006

AXP000090.1 · Oncolytic virus

Platform
HSV-2 (strain HG52, ICP34.5- ICP47-)
Originator
Binhui Biopharmaceutical
Sponsor
Binhui Biopharmaceutical

Names

NameTypeSource
BS-006preferred name, codecurator, ncit

Virus

Role
Oncolytic
Family
Orthoherpesviridae
Virus
herpes simplex virus 2 (NCBI Taxonomy 10310)
Strain
HG52
Replication
conditionally replicating
Modifications
ICP34.5 and ICP47 deleted
Transgenes
anti-PD-L1/CD3 bispecific antibody
Route
intratumoral
Source
evidence

Cross-references

NCI Thesaurus
C188176

Approvals

No regulatory approval recorded.

Clinical trials (3)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT05938296oHSV2-PD-L1/CD3-BsAb Administered Via Intratumoral InjectionSuspendedPhase 12023-12-192026-12-1929Solid Tumor
NCT07382531OH2 Injection in Combination With BS006 Injection for Advanced Solid TumorsRecruitingPhase 1/22023-09-072027-12-3130Solid Tumor
NCT05393440First-in-human (FIH) Phase I Trial of BS-006 in Cervical CancerUnknownPhase 12022-09-162023-12-3118Uterine Cervical Neoplasms

Recent changes

No changes recorded in its trials yet.

Notes

OH2 backbone armed with an anti-PD-L1/CD3 bispecific antibody instead of GM-CSF. A first-in-human phase I in cervical cancer is registered; dosing not confirmed from a primary report.

How to cite

BS-006 (AXP000090.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000090.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.